24СʱÈÈÃŰæ¿éÅÅÐаñ    

²é¿´: 1401  |  »Ø¸´: 3
±¾Ìû²úÉú 1 ¸ö ·­ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴

xiaotongxyz

ľ³æ (ÕýʽдÊÖ)

[½»Á÷] ÇóÖú·­ÒëÖÐÎÄÕªÒªÒ»·Ý£¬ÖØÉͽð±Ò£¬·­ÒëµÄºÃ¿É×·¼Ó

Ô­ÎÄ£º

¹ú²úÀûÅàͪÖÎÁÆÄÔѪ¹Ü²¡ËùÖ¾«ÉñÕϰ­ÁÆÐ§·ÖÎö

ÕªÒª£ºÄ¿µÄ£ºÌ½ÌÖ¹ú²úÀûÅàͪ£¨Ë¼ÀûÊæ£©ÖÎÁÆÄÔѪ¹Ü²¡ËùÖ¾«ÉñÕϰ­ÁÆÐ§ºÍ°²È«ÐÔ¡£·½·¨£ºËæ»ú³éÈ¡ÄÔѪ¹Ü²¡ËùÖ¾«ÉñÕϰ­30Àý£¬ÓÃ˼ÀûÊæÖÎÁÆ£¬²¢·Ö±ðÓÚÖÎÁÆÇ°¼°ÖÎÁƺóµÚ1¡¢2¡¢4¡¢8ÖÜÄ©²ÅÈ¥¼òÃ÷¾«Éñ²¡Á¿±í£¨BPRS)¡¢ÑôÐÔÖ¢×´ÒõÐÔÖ¢×´Á¿±í£¨PANSS£©¼°¸±×÷ÓÃÁ¿±í£¨TCSS£©ÆÀ¶¨ÁÙ´²ÁÆÐ§¼°²»Á¼·´Ó¦¡£½á¹û£ºBPRS×Ü·Ö¡¢PANSS×ֺܷ͸÷Ö¢×´ÆÀ·Ö¾ù½ÏÖÎÁÆÇ°ÏÔÖø½µµÍ£¬ÇÒÓÐÏÔÖø²îÒ죨P<0.01~0.05£©£¬ÓÐЧÂÊ£º90%£¬ÏÔЧÂÊ£º63%£¬³£¼û²»Á¼·´Ó¦ÊÇÌåÖØÔö¼Ó¡¢¾²×ø²»ÄÜ¡£½áÂÛ£ºË¼ÀûÊæ¶ÔÄÔѪ¹ÜËùÖª¾«ÉñÕϰ­°²È«ÓÐЧ£¬²»Á¼·´Ó¦ÉÙ£¬¾­¼ÃÊÊÓã¬ÖµµÃÁÙ´²ÍƹãʹÓá£
ÎÒ²»ÊÇÒ»¸öËæ±ãµÄÈË£¬ÎÒËæ±ãÆðÀ´²»ÊÇÈË£¬¹þ¹þ
ÒÑÔÄ   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

·Ç±ÈѰ³£

ľ³æ (СÓÐÃûÆø)

xiaotongxyz(½ð±Ò+20, ·­ÒëEPI+1):·­ÒëµÄ²»¹»×¨Òµ£¬ÓÐЩ·­Òë²»¹»×¼È·×¨Òµ 2010-04-30 01:18
Analysis of therapeutic effect of domestic Risperidone on non-psychotic disorders
resulting from cerebrovascular diseases

Abstract:
Purpose: to probe into therapeutic effect and security of domestic Risperidone on non-psychotic disorders resulting from cerebrovascular diseases.
Approach: to randomly draw 30 cases with non-psychotic disorders resulting from cerebrovascular diseases, treat them with Risperidone and then assess clinical curative effects and undesirable reactions with BPRS, PANSS and TCSS at the end of the first, second, fourth and eighth week before and after treatment. Result: aggregate score of BPRS and PANSS and each symptom score are considerablely much lower than that before treatment with significant variation
(P<0.01~0.05). The effective rate is 90% and developing rate is 63%. Common undesirable reactions are gain in weight and loss of sitting still.
Conclusion: Risperidone is secure and effective with a few undesirable reactions and deserves promotion and application because of its economically affordable and applicable trait on the treatment of non-psychotic disorders resulting from cerebrovascular diseases.
ѧ»áÈ¡Éᣡ
2Â¥2010-04-29 21:53:09
ÒÑÔÄ   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

pharmjackie

ľ³æ (ÕýʽдÊÖ)

xiaotongxyz(½ð±Ò+30):ǰ°ë²¿·Ö·­ÒëºÜºÃ£¬ºó°ë²¿·Ö²»¹»ÀíÏ룬רҵÐÔÔÙǿЩ¾ÍºÃÁË 2010-04-30 01:22
efficacy of Risperidone on brain vascular diseases caused psychonosema

Abstract  Object: to evaluate the efficacy and safety of Risperidone on brain vascular diseases caused psychonosema. Method: A total of 30 patients with psychonosema was randomly selected to treat with Risperidone, and clinical efficacy and adverse effect was recorded using BPRS, PANSS, and TCSS before treatment and at the end of 1, 2, 4, 8 weeks after treatment. Results: BPRS scores, PANSS scores and symptom scores decreased significantly compared to that of pre-treatment (P<0.01~0.05). Effective percentage is 90% while the obvious effective rate is 63%. Common adverse effects include: Weight gain, akathisia. Conclusion: Risperidone¡¯s effectiveness, safety and minor adverse effect makes itself worthy of clinical use.
3Â¥2010-04-29 22:10:21
ÒÑÔÄ   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

xiaotongxyz

ľ³æ (ÕýʽдÊÖ)

ÇóÖú½áÊø£¬ÉêÇë³·ÏúÌû×Ó£¬Í˻ؽð±Ò

ÇóÖúÒѽâ¾ö£¬ËäÓд𸴣¬µ«ÊDz»ÂúÒâ½á¹û£¬ÉêÇëÍË»ØÊ£Óà½ð±Ò
ÎÒ²»ÊÇÒ»¸öËæ±ãµÄÈË£¬ÎÒËæ±ãÆðÀ´²»ÊÇÈË£¬¹þ¹þ
4Â¥2010-05-07 11:58:31
ÒÑÔÄ   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ xiaotongxyz µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[»ù½ðÉêÇë] ÈËÆø²»ÐÐÁË +11 fansofjerry 2026-08-21 11/550 2026-08-25 11:04 by ¹Â¶ÀµÄÓ¢ÐÛ6
[½Ìʦ֮¼Ò] µ¼Ê¦Í²ۣºÎÒÔõô̯ÉÏÁËÕâô¸ö¼«Æ·Ñо¿Éú£¡ +3 ËÕ¶«ÆÂ¶þÊÀ 2026-08-23 3/150 2026-08-25 10:35 by shisan1313
[»ù½ðÉêÇë] 2026ÄêµÄ¹ú¼ÒÉç¿Æ»ù½ðÏîĿͨѶÆÀÉóµÄйæÔòÓëж¯Ïò¡¢ÐÂÌôÕ½ +5 process2012 2026-08-23 7/350 2026-08-25 09:42 by huixian257
[»ù½ðÉêÇë] Èç¹û´Ë¿ÌÄãÕýÔÚΪ¹ú»ù¸Ðµ½½¹ÂÇ£¬²»·ÁÀ´ÌýÌýÕâÊס¶»ù½ðÖ®Íâ¡· +7 scalable 2026-08-24 7/350 2026-08-24 23:01 by anata1209
[»ù½ðÉêÇë] ûÓÐÈκÎÏûÏ¢-ÊDz»ÊǾÍÁ¹ÁË +7 ͼÀ²Í¼À² 2026-08-24 8/400 2026-08-24 22:00 by maomao_da
[»ù½ðÉêÇë] ÄÜ·ñÍ˳ö²ÎÓëµÄÃæÉÏÏîÄ¿½â³ýÏÞÏî +21 koalala 2026-08-24 24/1200 2026-08-24 19:25 by ¼ÒÓëÔ¶·½
[»ù½ðÉêÇë] filecode£¬4¸öjtjcÁË +14 ziyangfang 2026-08-19 17/850 2026-08-24 18:37 by ¹þ¹þ¸ò£¿
[»ù½ðÉêÇë] ½¨Òé»ù½ð·¢²¼Ìáǰ¸ø³öÃ÷È·µÄʱ¼äµã +13 kulium 2026-08-21 16/800 2026-08-24 16:27 by superceng
[»ù½ðÉêÇë] ½ñÈÕ²»·Å°ñ£¿Íø´«¹ú×ÔȻԤ¼Æ 8 Ô 27 Èտɲé½á¹û +17 ҽѧÀÏÄк¢ 2026-08-20 21/1050 2026-08-24 14:21 by refreshing11
[»ù½ðÉêÇë] ¹À¼ÆÊÇÖÜËÄ +4 archvillain 2026-08-18 4/200 2026-08-24 13:53 by zzuzxg
[»ù½ðÉêÇë] ÈÃÎÒÖÐÒ»¸öÃæÉϰɣ¡ +13 ´óƼ1987 2026-08-20 16/800 2026-08-24 10:23 by ̫ɵÁË
[»ù½ðÉêÇë] ·Å°ñǰµÄ²»µ­¶¨ 20+4 snowwithsea 2026-08-19 17/850 2026-08-24 10:20 by echo8914667
[»ù½ðÉêÇë] ¿ÆÑй¶ùÌ«ÄÑÁË +18 ÎÒ4´ó°×²Ë 2026-08-20 19/950 2026-08-24 09:47 by ¿­¶÷¹ãÊ¢´ß»¯·ÖÎ
[»ù½ðÉêÇë] ʲôʱºò¿ª½±£¿ +10 CrisMessi 2026-08-18 11/550 2026-08-24 06:50 by ¿ªÐĵÄСʨ×Ó
[½Ìʦ֮¼Ò] Ìø²ÛºóÔÚÑÐÏîÄ¿Ôõô°ì£¿ +5 ¼òµ¥»¯xn 2026-08-22 10/500 2026-08-23 12:38 by ¼òµ¥»¯xn
[»ù½ðÉêÇë] ½ñÌì·Å°ñÂ𣿠+15 ²¼²¼ºÍÒ»¶þ 2026-08-19 16/800 2026-08-23 09:55 by ÕÅ´ºÉú
[»ù½ðÉêÇë] ¿´À´½ñÌì²»»á·Å°ñÁË£¿ +8 chengyan1220 2026-08-21 11/550 2026-08-21 17:52 by dcqxinyang
[»ù½ðÉêÇë] ʱ¼ä´ÁÓÖ±äÁË +13 wuchongjun 2026-08-20 19/950 2026-08-21 17:21 by ×Ïɼ´¼
[»ù½ðÉêÇë] ½ñÌì·Å°ñûϷÁ衃 +9 yuleib84 2026-08-19 11/550 2026-08-21 10:06 by gltch
[»ù½ðÉêÇë] ÖØÒªÏûÏ¢£¬ÖÐÎçϵͳÔÚά»¤ +11 yuleib84 2026-08-18 12/600 2026-08-20 11:09 by xskun
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û